Status:

COMPLETED

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborating Sponsors:

Aventis Pharmaceuticals

Eli Lilly and Company

Conditions:

Lung Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens...

Detailed Description

Upon determination of eligibility, patients will receive: Pre-operative * Docetaxel * Gemcitabine Post-operative * Docetaxel * Carboplatin * Radiation Therapy Patients with stage IB and II NSCLC wh...

Eligibility Criteria

Inclusion

  • To be included in this study, you must meet the following criteria:
  • Histologically confirmed non-small cell lung cancer
  • Must be operable candidate
  • Clinical stage IB, II, and select III non-small cell lung cancer are eligible
  • Measurable or evaluable disease
  • Able to perform activities of daily living with minimal assistance
  • Must be \> 18 years of age
  • Adequate bone marrow, liver or kidney
  • No previous chemotherapy or radiation therapy for non-small cell lung cancer
  • Moderate to severe peripheral neuropathy
  • Understand the nature of this study and give written informed consent.

Exclusion

  • You cannot participate in this study if any of the following apply to you:
  • Stage IV disease
  • History of prior malignancy within five years
  • Women who are pregnant or breast-feeding
  • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT00193427

Start Date

April 1 2004

End Date

December 1 2008

Last Update

March 3 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tennessee Oncology, PLLC

Nashville, Tennessee, United States, 37023

Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer | DecenTrialz